

ACS Cancer Conference 2025

March 12-14 | Phoenix, AZ

Genetics Access Pilot (GAP) ACS/CoC/NAPBC

Lee G Wilke, MD FACS

Senior Medical Director; Clinical Cancer Services

UW Health/Carbone Cancer Center

Professor of Surgery

ACS Cancer Programs
American College of Surgeons

The WHY: Genetic Testing in Individuals with Breast Cancer

- Genetic testing results inform risk of second breast cancers for newly diagnosed patients and have therapeutic implications. Results can inform screening for family members who receive testing.
- The American Society of Clinical Oncology (ASCO) and Society of Surgical Oncology issued a guideline in 2024 recommending that clinicians offer genetic testing for BRCA 1 and 2 for newly diagnosed patients (1) under the age of 65 years old, (2) >65 if eligible for PARP therapy (3) triple negative breast cancer, (4) male at birth and/or (5) family history suggestive of a genetic predisposition. (Bedrosian I, et al: Germline testing in patients with breast cancer: ASCO-SSO guideline. J Clin Oncol. 2024)
- American Society of Breast Surgeons (ASBrS) issued a consensus guideline in 2019 that stated that all newly diagnosed breast cancer patients should be offered testing for BRCA 1/2 and PALB2 and testing for other genetic mutations as the clinical scenario or patient's family history indicates.

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

GAP Project Team

- Lee Wilke, MD – NAPBC QI Chair
- Kathy Yao, MD – NAPBC Chair
- Kelley Chan, MD- ACS Scholar
- Shea Coates – ACS Quality Improvement Specialist
- Jill Dietz, MD – Former NAPBC Vice-Chair
- Sue Freidman-Advocate/FORCE
- Christine Jett- Genetic Counselor/Genetic Support Foundation
- Cary Kaufman, MD-Breast Surgeon/Private practice
- Meeghan Lautner, MD – CoC QIC committee
- Tony Nguyen, MD – NAPBC Committee Chair
- Eileen Reilly – ACS Quality Manager
- Ton Wang – Implementation expert
- Anthony (Tony) Yang, MD -CoC QIC Vice Chair

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

GAP Goals and Objectives

- **Goal:** This pilot project seeks to better understand effective models for and barriers to offering genetic testing to newly diagnosed breast cancer patients.
- **Aim:** Increase the number of newly diagnosed breast cancer patients offered genetic testing by 20% from baseline at CoC/NAPBC pilot sites from January 2025 to December 2025

Secondary Aims:

- Obtain baseline data of genetic testing in pilot sites for proposed population
- Identify structural and process barriers to achieve testing
- Develop and test interventions to address modifiable barriers to genetic testing
- Spread, scale, and disseminate findings

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Programmatic Outputs and Benefits

- Develop a suite of interventions (case studies, decision trees, etc)
- Improve patient access to testing
- Improve/streamline operational processes and enhance workflows
- Opportunity for networking and peer to peer learning
- Credit for standards
 - CoC: 7.3
 - NAPBC: 7.2 AND 4.4

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Long Term Goals

- Potential national QI collaborative in 2026
- Toolbox of tested interventions
- Dissemination of findings
- Outcomes:
 - All CoC/NAPBC programs have a system in place to identify patients for genetic testing
 - All CoC/NAPBC programs have a pathway to offer genetic testing for their patients
 - All patients interested in genetic testing receive testing

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Timeline

Date	Event
Nov 20	Informational webinar at 12pm CT
December 20	Applications are Due at 11:59p CT – 230 applications!
Jan 15	Applicants are notified of their selection status - 27 selected
Jan 31	Applicant kick off call
Feb 28	Pre-survey and chart review data due 20 patients seen Oct 1-Dec 31, 2023
April 15	Patients seen Jan 1-March 31, 2025 data due
April 25	Cohort Call
July 15	Patients seen April 1-June 31 data due
August 22	Cohort Call
Oct 15	Patients seen July 1-Sept 30 data due
Nov 14	Cohort call
Dec 15	Patients seen Oct 1- Nov 30 data due Potential wrap up/summary call

What are we measuring?

Description/ Definition	Measure Calculation (Numerator:/Denominator:)	Data Source Associated Data Collection Tool
% of newly diagnosed breast cancer patients diagnosed with triple negative offered genetic testing	<u>Numerator:</u> Number of patients diagnosed with triple negative breast cancer offered genetic testing <u>Denominator:</u> All newly diagnosed breast cancer patients diagnosed with triple negative breast cancer	Review of Patient Health Records
% of newly diagnosed breast cancer patients 51-65 years old offered genetic testing	<u>Numerator:</u> Number of patients aged 51-65 offered genetic testing <u>Denominator:</u> All newly diagnosed breast cancer patients between ages 51- 65	Review of Patient Health Records
% of newly diagnosed breast cancer patients aged 50 and younger offered genetic testing	<u>Numerator:</u> Number of patients aged 50 and younger offered genetic testing <u>Denominator:</u> All newly diagnosed breast cancer patients aged 50 and younger	Review of Patient Health Records


Data Submission

ACS Cancer Programs has submitted an IRB application for exempt/non-human subjects research status, and the exemption has been granted.

- Utilization of RED-Cap as a web-based interface secure to the American College of Surgeons
- Up to 20 case review forms per time period

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Program Characteristics (N=27)



Urban/Rural	N (%)
Large metropolitan	8 (30)
Small metropolitan	5 (19)
Suburban	6 (22)
Rural	8 (30)

Medicaid Population	N (%)
<20%	8 (30)
20-50%	9 (33)
50-75%	7 (26)
Unsure	3 (11)


Safety-Net	N (%)
Yes	11 (41)
No	10 (37)
Unsure	6 (22)

Self Reported Annual Breast Case Load: Mean 278, range 16-1541

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

ACS Cancer Conference 2025 | March 12-14 | Phoenix, AZ

Regional Representation



© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Preliminary Baseline Data

20 patients per site (2023 data)

Access to Genetic Counselor/Geneticist	N (%)
Yes, at least one on staff	9 (33)
Yes, we contract with a company	11 (41)
No, we do not have any available	7 (26)

We are doing a good job of offering and completing genetic testing on our newly diagnosed breast cancer patients (1 missing)	N (%)
Strongly agree	10 (39)
Agree	11 (42)
Neutral	2 (8)
Disagree	1 (4)
Strongly disagree	2 (8)

Who is ordering testing?	N (%)
Board certified/eligible American Board of Genetic Counselor	7 (27)
Board certified/eligible American Board of Medical Genetics and Genomics	1 (4)
Advanced genetics nursing certification from the American Nurses Credentialing Center	2 (8)
Advanced Clinical Genomics Nurse from the Nurse Portfolio Credentialing Committee	0
Licensed health care professional with Advanced Oncology Certified Nurse Practitioner credentials or equivalent certification from the Oncology Nursing Certification Corporation	1 (4)
Board certified/eligible MD with experience in cancer genetics	19 (74)
Other	12 (46)

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Preliminary Baseline Data (530 patients)

- Patient Characteristics

- Black 13 %; Hispanic 10%
- No Family history of breast cancer : 53%
- Median Age: 63
- Insurance
 - 3.4% None
 - 13% Medicaid
 - 37% Medicare

- Baseline Genetic Testing Rate

- 32-86% (Interquartile Range) with 0-95% among 27 programs

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Thank You and Questions

Thank you to the programs participating
& the GAP project team

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

ACS Cancer Conference 2025 | March 12-14 | Phoenix, AZ

ACS Cancer Programs
American College of Surgeons